RxDoctor Payments Data

Ada Andino

Family · Elizabeth, NJNPI 1609582741

Payments from drug & device makers

$2,050in general payments, 2019–2025

Across 102 payments — averaging $20.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$392
  • Novo Nordisk$318
  • GSK$275
  • Eisai Inc.$159
  • Lilly USA, LLC$146
  • AbbVie$142
  • plus $617 from 15 others

What the payments were for

  • Speaking & faculty fees$141%
  • Food & beverage$2,03599%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,050 in reported general payments places this provider in the 85th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol296$320,514
OzempicSemaglutide127$147,168
ProliaDenosumab82$143,867
LinzessLinaclotide153$137,802
Trelegy ElliptaFluticasone/Umeclidin/Vilanter131$106,041
VascepaIcosapent Ethyl189$102,728
JardianceEmpagliflozin64$83,291
RybelsusSemaglutide61$77,556
TrulicityDulaglutide71$76,392
Breztri AerosphereBudesonide/Glycopyr/Formoterol84$66,644
EliquisApixaban59$54,844
MyrbetriqMirabegron84$54,503
MounjaroTirzepatide46$48,873
XareltoRivaroxaban38$38,633
JanumetSitagliptin Phos/Metformin Hcl33$34,688

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$392$393,135405 claims
Novo NordiskOzempic, Rybelsus$318$224,724188 claims
AbbVieLinzess, Creon$142$167,541173 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy, Synjardy Xr, Trijardy Xr$45$166,692153 claims
AmgenProlia$47$143,86782 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$275$126,197175 claims
Lilly USA, LLCTrulicity, Mounjaro$146$125,265117 claims
MerckJanumet, Belsomra, Janumet Xr, Januvia$64$80,720111 claims
Johnson & JohnsonXarelto$33$38,63338 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$17$6,55011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,692 family providers in New Jersey.

Other family in Elizabeth

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →